There are currently 1342 clinical trials in Columbus, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Nationwide Children's Hospital, Ohio State University Comprehensive Cancer Center, Ohio State University and The Ohio State University. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study
NCT04372524
Recruiting
This study will validate a previously developed pediatric prognostic biomarker algorithm aimed at improving prediction of risk for the later development of chronic graft-versus-host disease (cGvHD) in children and young adults undergoing allogeneic hematopoietic stem cell transplant. By developing an early risk stratification of patients into low-, intermediate-, and high-risk for future cGvHD development (based upon their biomarker profile, before the onset of cGvHD), pre-emptive therapies aim... Read More
Gender:
All
Ages:
Between 0 years and 24 years
Trial Updated:
12/02/2023
Locations: Nationwide Children's Hospital, Columbus, Ohio
Conditions: Chronic Graft-versus-Host-Disease, Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation, Blood Cancer, Non-Malignant Hematologic and Lymphocytic Disorder
Register for Updates
Feasibility Trial of a Single Session of Crisis Response Planning for Youth at High Risk for Suicide
NCT06164106
Recruiting
The current study is a clinical trial, meaning a research study in which human subjects are prospectively assigned to one or more interventions to evaluate the effects of those interventions on health-related behavioral outcomes. Specifically, male and female adolescents with current suicidal intent will be randomly assigned to receive either a 1-hour session of virtual crisis response planning (CRP), a 1-hour session of in-person CRP, or a 1-hour session of standard crisis risk management (trea... Read More
Gender:
All
Ages:
Between 14 years and 18 years
Trial Updated:
12/01/2023
Locations: The Ohio State University, Columbus, Ohio
Conditions: Suicide Prevention
Register for Updates
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients
NCT03567889
Recruiting
The trial aims to evaluate the efficacy of Daromun neoadjuvant treatment followed by surgery and adjuvant therapy to improve in a statistically significant manner the recurrence-free survival (RFS) of Stage IIIB/C melanoma patients with respect to the standard of care (surgery and adjuvant therapy).
Gender:
All
Ages:
18 years and above
Trial Updated:
11/29/2023
Locations: Ohio State University Wexner Medical Center, Columbus, Ohio
Conditions: Melanoma Stage IIIB/C
Register for Updates
Trial of Vision Therapy for Intermittent Exotropia
NCT04487249
Recruiting
The main objective of this randomized trial comparing vision therapy to observation is to determine the short-term effectiveness of vision therapy on distance intermittent exotropia control. The results will help determine whether to proceed to a full-scale, long-term randomized trial.
Gender:
All
Ages:
Between 8 years and 16 years
Trial Updated:
11/28/2023
Locations: Ohio State University, Columbus, Ohio
Conditions: Intermittent Exotropia
Register for Updates
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
NCT04951219
Recruiting
A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: Aventiv Research Columbus, Columbus, Ohio
Conditions: Non-Alcoholic Fatty Liver Disease
Register for Updates
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With T-PLL
NCT04496349
Recruiting
This is a multi-center, open-label, phase IIa study to evaluate the pharmacokinetics (PK), safety, and efficacy of APG-115 as a single agent or in combination with APG-2575 in patients with T-PLL. The study consists of two parts. A total of 24-36 T-PLL patients will be enrolled.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: Ohio State University, Columbus, Ohio
Conditions: T-Prolymphocytic Leukemia
Register for Updates
TVMR With the Innovalve System Trial - Early Feasibility Study
NCT04919980
Recruiting
Study to evaluate the safety and performance of the Innovalve mitral valve replacement system
Gender:
All
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: OhioHealth Research Institute, Columbus, Ohio
Conditions: Mitral Valve Regurgitation (Degenerative or Functional)
Register for Updates
MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
NCT05286788
Recruiting
MEKTOVI (binimetinib) is an oral, highly selective reversible inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. The biological activity of binimetinib that has been evaluated bith in vitro and in vivo in a wide variety of tumor types In this Phase II, the drug will be used to treat pediatric patients diagnosed with recurrent Adamantinomatous Craniopharyngioma including patients who have undergone surgery and/or radiation therapy.
Gender:
All
Ages:
Between 1 year and 25 years
Trial Updated:
11/27/2023
Locations: Nationwide Children's Hospital, Columbus, Ohio
Conditions: Adamantinous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma
Register for Updates
Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
NCT04564339
Recruiting
The objectives of this study are to evaluate the safety and efficacy of ravulizumab administered by intravenous (IV) infusion compared to placebo and demonstrate proof-of-concept of the efficacy of terminal complement inhibition in participants with LN (LN Cohort) or IgAN (IgAN Cohort).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
11/22/2023
Locations: Clinical Study Site, Columbus, Ohio
Conditions: Lupus Nephritis, Immunoglobulin A Nephropathy
Register for Updates
CHaractErizing CFTR Modulated Changes in Sweat Chloride and Their Association With Clinical Outcomes
NCT03350828
Recruiting
This is a multicenter, cross-sectional, cohort study which will collect contemporary sweat chloride (SC) values from approximately 5000 Cystic Fibrosis (CF) patients prescribed and currently receiving commercially approved Cystic Fibrosis transmembrane conductance regulator (CFTR) modulator therapies.
Gender:
All
Ages:
4 months and above
Trial Updated:
11/21/2023
Locations: Nationwide Children's Hospital, Columbus, Ohio
Conditions: Cystic Fibrosis
Register for Updates
Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies
NCT04924322
Recruiting
The goal of the CRETE Studies is to investigate the newly identified age-dependent heterogeneity in the efficacy of enoxaparin in reducing the risk of central venous catheter-associated deep venous thrombosis in critically ill children.
Gender:
All
Ages:
17 years and below
Trial Updated:
11/20/2023
Locations: Nationwide Children's Hospital, Columbus, Ohio
Conditions: Deep Venous Thrombosis
Register for Updates
Effect of Fetal Aortic Valvuloplasty on Outcomes
NCT05386173
Recruiting
In one of the most severe congenital heart defects, hypoplastic left heart syndrome (HLHS), the left ventricle is underdeveloped and the prognosis is worse than in most other heart defects. The underdevelopment can occur gradually during fetal growth caused by a narrowing of the aortic valve. At some international centers, such fetuses are treated with a balloon dilation of the narrowed valve, but there is no scientifically sound evidence that this treatment is effective. The aim of this study... Read More
Gender:
All
Ages:
Between 23 weeks and 31 weeks
Trial Updated:
11/18/2023
Locations: Congenital Heart Collaborative, Nationwide Children's Hospital, Columbus, Ohio
Conditions: Congenital Heart Disease, Aortic Valve Stenosis, Fetal Cardiac Disorder, Hypoplastic Left Heart Syndrome
Register for Updates